LUPIN - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.8
✅ Positive
Lupin demonstrates strong revenue growth driven by a 39.2% quarter-on-quarter profit increase, coupled with healthy ROCE of 26.2%. The company's strategic spin-off of oncology assets into Kaveri Therapeutics signals a focused approach to high-growth segments.
⚠️ Limitation
Despite robust profitability, the stock trades at a relatively high P/E ratio compared to its industry peers, reflecting broader market sentiment and potential growth expectations. FII holding decreasing coupled with DII holding decrease can be seen as a negative signal.
📉 Company Negative News
Recent news indicates analyst views on Trump's generic tariff roadmap which may pose headwinds for Lupin’s business if tariffs are implemented. The spin-off of oncology assets into Kaveri Therapeutics is presented as positive but relies on the success of this new entity.
📈 Company Positive News
Lupin has spun off its oncology assets into a separate company called Kaveri Therapeutics, suggesting focus and potential future growth in this segment. The stock gained around 1% following news of this spin-off.
🏭 Industry
The pharmaceutical sector is characterized by intense competition, patent expirations leading to generic drug proliferation, and increasing regulatory scrutiny. Companies within the industry must constantly innovate, manage costs effectively, and secure market access to maintain profitability. India’s pharmaceutical market benefits from government initiatives promoting domestic manufacturing but faces challenges regarding pricing pressures.
🧾 Conclusion
Lupin presents a compelling investment opportunity with its solid financials and growth trajectory, particularly considering the current undervaluation indicated by a PEG ratio of 0.14. An entry zone between ₹2,300 and ₹2,350 offers potential upside as the market recognizes its strategic focus and robust profitability. Long-term holding guidance suggests retaining the stock with periodic review based on evolving industry dynamics and company performance – maintain a buy position with a target price of 2800₹ in 3-5 years.
NIFTY 50 · Fundamental
- No data available.
NEXT 50 · Fundamental
- No data available.
MIDCAP · Fundamental
- No data available.
SMALLCAP · Fundamental
- No data available.